Detection of hepatocellular carcinoma using glycomic analysis

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1808-1813

  Goldman, Radoslav ^a,f   Ressom, Habtom W ^a   Varghese, Rency S ^a   Goldman, Lenka ^a   Bascug, Gregory ^a   Loffredo, Christopher A ^a   Abdel Hamid, Mohamed ^b   Gouda, Iman ^c   Ezzat, Sameera ^d   Kyselova, Zuzana ^e   Mechref, Yehia ^e   Novotny, Milos V ^e  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MINIA UNIVERSITY   (Egypt)

^c NATIONAL CANCER INSTITUTE   (Egypt)

^d MENOUFIA UNIVERSITY   (Egypt)

^e INDIANA UNIVERSITY   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN DERIVATIVE; GLYCOPROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME RELEASE; FEMALE; GLYCOBIOLOGY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHYLATION; OUTCOME ASSESSMENT; POPULATION DYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; VIRUS INFECTION;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYSACCHARIDES; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 63549111877     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5261     Document Type: Article

References (38)

1. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LAM. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N YAcad Sci 2003;963:13-20.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States [see comments]. N Engl J Med 1999;340:745-50.
3. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-9.
4. Ezzat S, Abdel-Hamid M, Eissa SA, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005;208:329-39.
5. Perz JF, Alter MJ. The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol 2006;44:441-3.
6. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F,Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006;44:455-61.
7. Di Bisceglie AM, Lyra AC, Schwartz M,etal. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98:2060-3.
8. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. JHepatol 1998;28:930-8.
9. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-35.
10. Schwartz JM, Ham JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2003;6:465-72.
11. Lopez LJ, Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2004;20:248-53.
12. Gupta S, Bent S, Kohlwes J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003;139:46-50.
13. Filmus J, Capurro M. Glypican-3 and afetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 2004;8:207-12.
14. Chignard N, Shang S, Wang H, et al. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: detection of generated fragments in patient sera. Gastroenterology 2006; 130:2010-22.
15. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer2005;5:845-56.
16. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive α-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res1993;53:5419-23.
17. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive α-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-upof cirrhotic patients. Hepatology1995;22:802-7.
18. Marrero JA, Romano PR, Nikolaeva O, et al. GP73,a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005;43:1007-12.
19. Comunale MA, Lowman M, Long RE, et al. Proteomic analysis of serum associated fucosylated glyco-proteins in the development of primary hepatocellular carcinoma. J Proteome Res 2006;5:308-15.
20. Turner GA. N-glycosylation of serum proteins in disease and its investigation using lectins. Clin Chim Acta1992;208:149-71.
21. Lee SJ, Evers S, Roeder D, et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science2002;295:1898-901.
22. Kyselova Z, Mechref Y, Bataineh MM, et al. Alterations in the serum glycome due to metastatic prostate cancer. JProteome Res 2007;6:1822-32.
23. Zhao J, Qiu W, Simeone DM, Lubman DM. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res 2007;6:1126-38.
24. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-basedtotal serum protein glycomics. NatMed 2004;10:429-34.
25. Kang P, Mechref Y, Klouckova I, Novotny MV. Solid-phase permethylation of glycans for mass spectrometric analysis. Rapid Commun Mass Spectrom 2005;19:3421-8.
26. Nada O, Abdel-Hamid M, Ismail A, et al. Theroleof the tumor necrosis factor (TNF)-Fas L and HCV in the development of hepatocellular carcinoma. J Clin Virol 2005;34:140-6.
27. Abdel-Hamid M, Edelman DC, Highsmith WE, Constantine NT. Optimization, assessment, and proposed use of a direct nested reverse transcription polymerase chain reaction protocol for the detection of hepatitis C virus. JHumVirol1997;1:58-65.
28. AJCC cancer staging manual. 6th ed. NewYork: SpringerVerlag; 2002.
29. Mechref Y, NovotnyMV. Mass spectrometric mapping and sequencing of N-linked oligosaccharides derived from submicrogram amounts of glycoproteins. Anal Chem1998;70:455-63.
30. Ressom HW, Varghese RS, Drake SK, et al. Peak selection from MALDI-TOF mass spectra using ant colony optimization. Bioinformatics 2007;23:619-26.
31. Mechref Y, Novotny MV, Krishnan C. Structural characterization of oligosaccharides using MALDI-TOF/TOF tandem mass spectrometry. Anal Chem 2003; 75:4895-903.
32. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis 2005;9:235-51, vi.
33. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. JCancer ResClin Oncol 2004;130:417-22.
34. Morelle W, Flahaut C, Michalski JC, Louvet A, Mathurin P, Klein A. Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glyco-biology2006;16:281-93.
35. Liu XE, Desmyter L, Gao CF, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007;46:1426-35.
36. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142-9.
37. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer2004;4:309-14.
38. Block TM, Comunale MA, Lowman M, et al. Useof targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 2005;102:779-84.